Second allogeneic hematopoietic stem cell transplantation (HSCT2) is a frequently used treatment option for relapse of acute leukemia after first allogeneic transplantation. Remission can be induced in selected patients, but data on long-term outcome and finally cure are limited. To estimate the long-term results of HSCT2, we retrospectively analyzed the course of 286 patients receiving myeloablative HSCT2 between 1985 and 2000, with a median follow-up of 11.3 years. Overall survival (OS) and leukemia-free survival (LFS) at 10 years from HSCT2 were 10 ± 2 and 7 ± 2%, respectively. Cumulative 10-year incidence of relapse and non-relapse mortality were 58 ± 3% and 35 ± 3%, respectively. CR at HSCT2, an interval from first transplant to relapse 410 months and TBI as part of the conditioning for HSCT2 favorably influenced LFS and OS. Patients with all three favorable factors had a 10-year OS of 36 ± 10% and LFS of 25 ± 9%, whereas patients showing no favorable factor had all died before year 5. Although retrospective, the long follow-up of this analysis supports the curative potential of alloHSCT2 in selected patients, who might be identified in advance, based on prognostic factors.
INTRODUCTION
Optimal treatment for patients with acute leukemia relapsing after a first allogeneic hematopoietic stem cell transplantation (HSCT) is still an open question. 1 Options include chemotherapy, donor lymphocyte infusion [2] [3] [4] [5] or a second allogeneic transplantation (HSCT2) [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Most published studies on HSCT2 are limited by small patient numbers, wide heterogenicity of diagnoses, conditioning regimens and patient age (even including both adult and children), and in particular by short median follow-up, rarely exceeding 3 years from HSCT2. Hence, data on long-term outcome of a homogenous population, suggesting cure of relapsed acute leukemia, are lacking. Against this background, outcome and prognostic factors were analyzed in patients undergoing HSCT2 for acute leukemia relapse after a first allograft before the year 2000, with a median follow-up of 410 years.
PATIENTS AND METHODS
Data were retrospectively collected from the EBMT registry. All patients affected by acute leukemia relapse after a first allograft and undergoing allogeneic HSCT2 between 1985 and 2000 were included. Clinical records from a total of 286 consecutive patients (166 males and 120 females) from 120 European centers were reviewed. Median age at HSCT2 was 30 years (range: 18-61). The series comprised 166 (58%) AML and 120 (42%) ALL patients. Median time from first transplant to relapse was 305 days (range: 10-4991), while median time from first to second transplant was 440 days (range: 57-5026). Following the first transplant, acute and chronic GvHD (aGvHD, cGVHD) had developed in 87 and 36 patients, respectively.
At the second HSCT, the donor was an HLA identical sibling in 240 patients (84%), syngenic in 8 (3%), matched unrelated in 22 (8%), mismatched unrelated in 4 (1%) and haploidentical in 12 (4%). Six patients who had received an alternative donor graft at first transplant (five haploidentical and one unrelated), received an HLA identical graft at HSCT2. Source of stem cells was bone marrow (BM) in 147 patients (51%) and peripheral blood (PB) in 139 (49%). Only 11/241 informative patients (5 BM and 6 PB) received a T-cell-depleted graft, and 3/147 received ATG. Conditioning for HSCT2 was myeloablative in all cases. As in other studies, 19 the applied regimen showed a broad variety, with Busulfan-and Melphalan-based protocols being most frequently used. TBI was part of the conditioning for HSCT2 in 17% of patients; 14 patients received TBI before both transplants. At time of HSCT2, 112 patients (39%) were in CR (CR2 in 27%, ⩾ CR3 in 12%), 174 (61%) patients had active disease. Table 1 provides further details on HSCT1, relapse and HSCT2.
infiltration of a representative BM smear. LFS was defined as survival without relapse; patients alive without relapse were censored at the time of last contact. OS was based on death from any cause. NRM was defined as death without previous relapse. Surviving patients were censored at the time of last contact. The probabilities of OS and LFS were calculated using the Kaplan-Meier estimator. NRM and RI were calculated by using the cumulative incidence estimator, adjusting for competing risks. Age was included as continuous variable, chronic GVHD after second HSCT was analyzed as a time-dependent variable.
A Cox proportional hazards model was used for multivariate regression. All variables known as potentially prognostic factors or associated with a P-value o0.10 by univariate analysis were included A stepwise procedure was then applied for variable selection with a P-value of 0.05, in order to develop a prognostic classification easy to use for clinicians, allowing a good discrimination and identification of patients who could benefit from second transplantation.
Results are expressed as hazard ratio (HR) with 95% confidence interval (CI). All tests were two-sided. The type-1 error rate was fixed at 0.05 for determination of factors associated with time-to-event outcomes. Statistical analyses were performed with SPSS 19 (SPSS Inc/IBM, Armonk, NY, USA) and R 3.0.1 (R Development Core Team, Vienna, Austria) software packages.
RESULTS
At a median follow-up of 11.3 years (range: 1.2-23) among survivors, 30 patients (10%) were alive, 21 (7%) with no evidence of disease. OS and LFS were, respectively, 21 ± 2 and 15 ± 2% at 2 years, 14 ± 2 and 12 ± 2% at 5 years and 10 ± 2 and 7 ± 2%; at 10 years from HSCT2 ( Figure 1 ). The 10-year CIR was 58 ± 3%, showing only low increase as compared with year 2 (52 ± 3%) and 5 (55 ± 3%). Non-relapse-mortality was 32 ± 3, 33 ± 3 and 35 ± 3% at 2, 5 and 10 years, respectively. Information on ANC recovery was available for 255 patients: 32 (12.5%) did not engraft; 222 (87.1%) engrafted; and one patient had a secondary graft failure.
After HSCT2, acute GVHD grades II-IV occurred in 85/247 (34%) evaluable patients, reaching grades III-IV in 49/247 (20%); 124 patients did not experience any aGvHD neither after first nor second HSCT. Causes of death included progressive disease (n = 136), GVHD (n = 29), infection (n = 34), veno-occlusive disease (n = 15), interstitial pneumonitis (n = 15) and miscellaneous (n = 19). Abbreviations: HSCT = hematopoietic stem cell transplantation; TCD = T-cell depletion; NA = not applicable; n. r. = not reported. a The median dose of TBI in 24 informative patients was 12 Gy (range: [8] [9] [10] [11] [12] [13] [14] .
b Chemotherapy-based conditioning showed a great variety with 420 different regimen used. The most frequently used protocols were Busulfan-based (+ Cyclophosphamide, 41%, +other drugs, 19%), Melphalan-based (18%), Cyclophosphamide-based (11%), and VP16 based (6%) of informative patients, respectively. Table 2 shows the results from the univariate analysis of factors potentially associated with outcome after alloHSCT2; patient age, CR at HSCT2, a longer interval between HSCT1 and relapse, TBI as part of conditioning for HSCT2, and BM as graft source for HSCT2 were correlated with superior OS, LFS and CIR. PB as graft source for HSCT2 was the only parameter associated with reduced NRM.
Multivariate analysis was performed to confirm prognostic factors (Table 3) . PBSC graft for HSCT2 and interval from HSCT1 to relapse more than 10 months were associated with reduced NRM after HSCT2. CR at HSCT2, BM grafts for HSCT2, use of TBI and interval from HSCT1 to relapse more than 10 months were associated with lower CIR. For both OS and LFS, remission duration after first HSCT, disease status at HSCT2, and the use of TBI within the conditioning for HSCT2 were decisive for better outcome due to a decrease relapse incidence. Concerning graft source, the lower CIR after HSCT2 using BM was compensated by a higher NRM, and therefore showed no significant influence on the composite end points LFS and OS. cGvHD after HSCT2 was not associated with improved outcome either in this model.
Outcome according to the three prognostic factors are shown in Table 4 and Figure 2 . In patients bearing no adverse factor, 10-year OS and LFS were 36 ± 10% and 25 ± 9%, respectively, decreasing to 17 ± 5% and 13 ± 4% in patients bearing 1 and to 6 ± 3% and 3 ± 2% among patients bearing 2 adverse factors. No patient with all three adverse factors became a long-term survivor (Po 0.0001).
DISCUSSION
Patients with acute leukemia relapsing after a first allograft have a poor prognosis with a survival of only a few months without further treatment. Remissions after re-induction chemotherapy can be as high as 70%, but overall survival rarely exceeds 15-20% at 2 years. 5, 18 Donor lymphocyte infusion can be an option, but unlike patients with chronic myelogenous leukemia, patients with acute leukemia rarely experience long-term benefit 20 . A second allogeneic transplant is another frequently used strategy, however, this might be limited by a high rate of both relapse and NRM. 19 Outcome after HSCT2 has been retrospectively studied earlier by many groups, including our own. 11 However, besides great heterogeneity of cohorts with respect to age, diagnose and applied transplant regimen, studies are limited by a short follow-up, rarely exceeding 3 years. Hence, data on longterm observation is warranted to justify statements on the curative potential of HSCT2, comparable to long-term data analyzing the outcome after novel transplant strategies such as reduced intensity regimen for first allogeneic HSCT. 21, 22 In the present study on a cohort of 286 patients with a 410-year median follow-up, it could be shown for the first time that both relapse and NRM are extremely rare events beyond 2, and particularly beyond 5 years from HSCT2, nearly resulting in a plateau of the survival curves among patients surviving five years and beyond. This observation underscores the potential for cure after allogeneic HSCT2 in selected patients. As after HSCT1, 23, 24 being alive in CR at 2 years from HSCT2 is highly predictive for long-term outcome after HSCT2. However, the plateau still remains at a rather low level, which, according to previous data from our registry and other groups, 10,11,13 has not significantly improved over time. This is mostly due to the failure to achieve long-term control of the leukemia, even by a second conditioning and application of allogeneic immune effector cells. Further, inferior outcome is also a consequence of the failure to reduce TRM of HSCT2 during the last decade, which is in contrast to a clear improvement in TRM over time after first transplant. 25 Several factors have been reported to impact on the outcome after second transplant, such as younger age, absence of GvHD, 10, 26 chronic GvHD after HSCT2 10 or remission status at time of HSCT2. 6, 9, 11, 14, 19 The present study confirmed the longterm advantage for both OS and LFS of a longer interval from first transplant to relapse, the achievement of CR before HSCT2 and the use of TBI at HSCT2. As in other studies, for example, 19 no differences could be detected among patients suffering from AML vs ALL, which is why a combined analysis was performed. Conclusions drawn in previous studies and our analysis seem to be valid for both forms of acute leukemia. Abbreviations: CIR = cumulative incidence of relapse; cGvHD = chronic GvHD; HSCT = hematopoietic stem cell transplantation; LFS = leukemiafree survival; NMR = non-relapse mortality; OS = overall survival; SC = stem cells.
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Notably, patients bearing all three positive factors showed a 10-year OS of 36 ± 10% and LFS of 25 ± 9%, whereas patients without any of the positive factors, had all died before 5 years from HSCT2. Remission duration and controlled disease before start of conditioning are well established factors for outcome after a second transplant both in the related 8, 15, 20 and unrelated setting. 19 In contrast, the role of TBI within the conditioning for second transplant is not clear. Some authors 10, 11 have observed a positive effect of TBI for HSCT2, while others 13, 19 have not. Our data support an advantage of TBI before HSCT2 for long-term outcome. The lower relapse rate after TBI (even reaching significance in the multivariate model) might point toward an improved antileukemic activity. However, it should be considered that most of the patients receiving TBI at HSCT1 were not selected for TBI before HSCT2 for unknown reasons. Hence, the number of TBI recipients at HSCT2 was relatively low, and only 14 patients received TBI before both transplants.
The use of PBSC at second transplant was significantly associated with a lower NRM, but a higher CIR. A similar influence on CIR had been reported in an earlier analysis, 11 but not in other studies. 13, 19 So far, no study has shown any significant influence of graft source on survival after HSCT2, whereas PBSC grafts were advantageous in several studies on first transplant for high-risk AML. 27, 28 In our study, increased NRM after compensated for the decrease in CIR. With respect to donor change for HSCT2, unfortunately, insufficient data were available in our cohort. However, a recent retrospective report did not show a relevant improvement in OS, when a new donor was used. 19 Within the limitations of a retrospective registry study, this analysis underscores the curative potential of myeloablative HSCT2 in selected patients by the longest follow-up reported so far. Our data suggest, that candidates for HSCT2 can be identified in advance, based on a longer interval from the first transplant procedure and achievement of CR before HSCT2. Moreover, TBI-based conditioning, and strategies to reduced TRM after HSCT2 may improve outcome. As a consequence, HSCT2 seems to be a real option in patients with a longer remission after HSCT1, who have a chemo-sensitive disease. Patients with early and/or refractory relapse have by far an inferior prognosis, which is why an experimental therapy or limitation of treatment to palliation might be discussed.
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